ASSEMBLY APPROPRIATIONS COMMITTEE
STATEMENT TO
[First Reprint]
ASSEMBLY, No. 4163
STATE OF NEW JERSEY
DATED: DECEMBER 16, 2024
The Assembly Appropriations Committee reports favorably Assembly Bill No. 4163 (1R).
This bill requires health insurers to cover biomarker testing. Under the bill, health insurance carriers (including health service corporations, hospital service corporations, medical service corporations, commercial individual and group health insurers, health maintenance organizations, entities contracted to administer health benefits in connection with the State Health Benefits Program and School Employees’ Health Benefits Program, and Medicaid) are to cover testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an individual’s disease or condition when the test is supported by medical and scientific evidence. The evidence includes, but is not limited to: (1) labeled indications for an FDA-approved or -cleared test; (2) indicated tests for an FDA-approved drug; (3) warnings and precautions on FDA-approved drug labels; (4) Centers for Medicare and Medicaid Services National Coverage Determinations or Medicare Administrative Contractor Local Coverage Determinations; or (5) nationally recognized clinical practice guidelines and consensus statements. Coverage is to be provided in a manner that limits disruption, including multiple biopsies or biospecimen samples, in the care of an individual.
The bill also stipulates that utilization review decisions concerning coverage provided under the bill are to be made in accordance with guidelines and timeframes already present in current law.
FISCAL IMPACT:
The Office of Legislative Services (OLS) estimates that requiring health insurance carriers to provide coverage for biomarker testing will result in annual indeterminate expenditures increases to the State, to local governments that participate in the State Health Benefits Program, and to school districts that participate in the School Employees’ Health Benefits Program.
The OLS estimates that requiring health insurance carriers to provide coverage for biomarker testing will result in an annual indeterminate expenditure impact for GetCoveredNJ, the State-based health insurance marketplace.
The OLS estimates that requiring health insurance carriers to provide coverage for biomarker testing will result in annual net expenditures increases of $372,000 to $670,000 for the NJ FamilyCare program, which encompasses the State Medicaid program and the Children’s Health Insurance Program.